Astra Zeneca making multi billion business in the USA

Monday, 23 April 2012
AstraZeneca acquires US-based Ardea Biosciences for $32 per share, making the purchase price amounts to about 1.26 billion U.S. dollars including existing cash.

Astra Zeneca, with CEO David Brennan, acquires US-based Ardea Biosciences for $ 32 per share, making the purchase price amounts to approximately 1.26 billion dollars - equivalent to Skr8.4 billion - including existing cash according to a press release.

Ardea is a biotechnology company in San Diego that focuses on developing small molecule drugs. Ardeas clinically most advanced product candidate, lesinurad (formerly known as RDEA594), is currently in Phase 3 as a potential treatment for chronic management of hyperuricemia in patients with gout.

The purchase price of approximately 1.26 billion dollars, including existing cash, representing a premium of 50 percent based on the volume weighted average price for one month and 54 percent based on the closing price on Friday, 20 April 2012.
By Scancomark.se Team

What do you think about this article or us? Please leave a comment. Thank you!